Skip to main content
Clinical Trials/NCT03921229
NCT03921229
Completed
N/A

Feasibility, Acceptability, and Pilot Randomized Controlled Trial of a Tele-Coaching Intervention to Improve Treatment Adherence in Cystic Fibrosis

Boston Children's Hospital6 sites in 1 country31 target enrollmentJanuary 13, 2020
ConditionsCystic Fibrosis

Overview

Phase
N/A
Intervention
Not specified
Conditions
Cystic Fibrosis
Sponsor
Boston Children's Hospital
Enrollment
31
Locations
6
Primary Endpoint
Intervention acceptability for patients assessed by Likert scale
Status
Completed
Last Updated
3 years ago

Overview

Brief Summary

This is a prospective, multicenter pilot study to investigate the feasibility and preliminary effectiveness of a tailored tele-coaching intervention to enhance medical adherence in patients with CF.

Detailed Description

This is a prospective, multicenter pilot study to test the feasibility and acceptability of a tele-coaching intervention and its implementation in patients with CF (ages 14-25 years), and to obtain estimates of treatment effects across a range of key outcome measures (e.g., global adherence, change in treatment barriers, specific improvement in adherence, etc.)

Registry
clinicaltrials.gov
Start Date
January 13, 2020
End Date
February 1, 2023
Last Updated
3 years ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Gregory Sawicki

Co-Chair of Success with Therapies Research Consortium

Boston Children's Hospital

Eligibility Criteria

Inclusion Criteria

  • COACH Participants:
  • Be a CF-focused clinician employed by one of the study sites, including: social workers; respiratory therapists, pharmacists, nurse practitioners, nurses, mental health coordinators, dieticians, and psychologists.
  • PATIENT Participants:
  • Male or female ≥ 14 and ≤ 25 years of age;
  • Documentation of a CF diagnosis as evidenced by one or more clinical features consistent with the CF phenotype and one or more of the following criteria: (a) sweat chloride \> 60 mEq/L by quantitative pilocarpine iontophoresis test (QPIT), and/or (b) two well-characterized mutations in the CFTR (cystic fibrosis transmembrane conductance regulator) gene;
  • Has been prescribed one or more respiratory nebulized medications, such as: (a) dornase alfa, (b) hypertonic saline, (c) inhaled tobramycin, (d) inhaled aztreonam, (e) inhaled colistimethate \*and/or\* uses a vest device for airway clearance;
  • If taking, or anticipating to start on, Trikafta, has been taking the modulator for 6 weeks prior to enrolling in the study;
  • Has access to necessary resources for participating in a technology-based intervention: (a) mobile phone, tablet, computer, or digital camera capable of capturing and sending a digital image, and access to Internet; (b) an email account;
  • Is English-speaking;
  • Endorsed score of ≥3 on any treatment component on the CF-CBS at Enrollment Visit.

Exclusion Criteria

  • COACH Participants:
  • Anticipated change in CF Center during study period;
  • Physicians (MD, DO, or equivalent degree);
  • Advanced practice providers (e.g., APRN, PA) who serve as the primary provider in the CF clinic setting; and
  • Site research coordinator designated for this study.
  • PATIENT Participants:
  • Participation in the previous Tele-coaching study;
  • Anticipated transition to another CF care center within study period;
  • Planned or scheduled hospitalization between consent and start of intervention;
  • Self-reported current or planned pregnancy;

Outcomes

Primary Outcomes

Intervention acceptability for patients assessed by Likert scale

Time Frame: up to 30 months

This measure was developed for this specific study to evaluate feasibility and acceptability of the intervention through aspects of usability, quality, and satisfaction. Assessed by 5 point Likert Scale: Strongly disagree, Disagree, Neither Agree or Disagree, Agree, Strongly Agree.

Recruitment and feasibility

Time Frame: up to 30 months

Recruitment and feasibility will be evaluated using the percentage of screen failures which are the number of eligible participants who do not score at least a three on any given treatment component for the CF-CBS amongst all eligible participants.

Patient attrition

Time Frame: up to 30 months

Patient attrition will be measured as the percentage of participants who do not receive a sufficient dose of the intervention.

Intervention acceptability for coaches assessed by Likert scale

Time Frame: up to 30 months

This measure was developed for this specific study to evaluate feasibility and acceptability of the intervention through aspects of usability, quality, and satisfaction. Assessed by 5 point Likert Scale: Strongly disagree, Disagree, Neither Agree or Disagree, Agree, Strongly Agree.

Secondary Outcomes

  • Change in treatment barriers(Day 1 to approximately week 51)
  • Mean change in global adherence(Day 1 to approximately week 51)

Study Sites (6)

Loading locations...

Similar Trials